Anti-cholesterol statins linked to blood pressure reduction
16 Apr 2008

Statins prescribed for high cholesterol appear to result in a "modest but significant" reduction in blood pressure, a report claims.

A double-blind placebo-controlled study was carried out on 973 men and women with no known cardiovascular disease or diabetes.

Participants were given either 20 mg of simvastatin, 40 mg of pravastatin or placebo for a period of six months.

Blood pressure readings were taken at the start of the trial and followed up at months one and six, as well as two months after the study's conclusion.

Reductions in both systolic and diastolic blood pressure readings were noted in patients taking both simvastatin and pravastatin.

Researchers have linked the findings with a reduced risk of stroke and cardiovascular events reported by patients taking statins.

"We found that statins lower both systolic and diastolic blood pressure, and that the effect extends to patients with pre-hypertension, those with normal blood pressure and persons not on blood-pressure lowering medications," said lead author Beatrice Golomb from the University of California.

"While reductions in blood pressure with statins were measurable as early as one month into the trial, the lowered blood pressure was significant at six months," she added.

The findings are reported in the April 14th edition of the journal Archives of Internal Medicine.

Click here to learn more about cholesterol

Print Article    Bookmark

• Cholesterol treatment receives US approval 16/12/08
• Study confirms no interference between cholesterol and lymphoma treatments 09/12/08
• New game could help tackle obesity and diabetes in kids, expert claims 04/12/08
• Some "good cholesterol" not good enough, study suggests 02/12/08
• Study links grapes with reduced cardio risk 29/10/08

• ZOCOR (statin) - 51.11%
  ... cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non- pharmacological measures is inadequate. To lower LDL:HDL ratio and total cholesterol ...
  
  
• LIPITOR (statin) - 50.64%
  Adjunct to diet for reduction of elevated total cholesterol, LDL- cholesterol, apolipoprotein B, and triglycerides in patients with primary hypercholesterolaemia, heterozygous and homozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non ...
  
  
• Simvastatin (statin) - 50.64%
  As an adjunct to diet for reduction of total cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non- pharmacological measures is inadequate ...
  
  
• LESCOL XL (statin) - 49.42%
  As an adjunct to diet for the reduction of elevated total cholesterol (total-C), low- density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B) and triglycerides (TG) levels and for the increase of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolaemia ...
  
  
• LIPOSTAT (statin) - 48.68%
  ... procedure in patients with a history of either a myocardial infarction or unstable angina pectoris and a total serum cholesterol level in excess of 4.8mmol/L or a LDL- cholesterol in excess of 3.2mmol/ L. Coronary atherosclerotic disease: adjunct to diet to slow progressve course of coronary ...
  
  
• CHOLESTAGEL Film-Coated Tablets - 47.95%
  ... reduction in LDL-cholesterol (LDL-C) levels in patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone. Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total and LDL-cholesterol in patients with isolated ...